Cargando…

Rescue therapy with adefovir in decompensated liver cirrhosis patients with lamivudine-resistant hepatitis B virus

BACKGROUND/AIMS: Adefovir dipivoxil (ADV) is a nucleotide analogue that is effective against lamivudine-resistant hepatitis B virus (HBV). The aim of this study was to determine the long-term clinical outcomes after ADV rescue therapy in decompensated patients infected with lamivudine-resistant HBV....

Descripción completa

Detalles Bibliográficos
Autores principales:	Woo, Hyun Young, Choi, Jong Young, Yoon, Seung Kew, Suh, Dong Jin, Paik, Seung Woon, Han, Kwang Hyub, Um, Soon Ho, Kim, Byung Ik, Lee, Heon Ju, Cho, Mong, Lee, Chun Kyon, Kim, Dong Joon, Hwang, Jae Seok
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Association for the Study of the Liver 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4099332/ https://www.ncbi.nlm.nih.gov/pubmed/25032183 http://dx.doi.org/10.3350/cmh.2014.20.2.168

Ejemplares similares

Adefovir Dipivoxil Alone or in Combination with Ongoing Lamivudine in Patients with Decompensated Liver Disease and Lamivudine-resistant Hepatitis B Virus
por: Kim, Kang Mo, et al.
Publicado: (2005)

Long-Term Outcomes and Dynamics of Mutants Associated with Lamivudine-Adefovir Rescue Therapy in Patients with Lamivudine-Resistant Chronic Hepatitis B
por: Kim, Jihyun, et al.
Publicado: (2015)

Adefovir- or Lamivudine-Induced Renal Tubular Dysfunction after Liver Transplantation
por: Lee, Jae Geun, et al.
Publicado: (2015)

Evaluating the efficacy of switching from lamivudine plus adefovir to tenofovir disoproxil fumarate monotherapy in lamivudine-resistant stable hepatitis B patients
por: Lee, Heon Ju, et al.
Publicado: (2018)

Long-term outcomes of two rescue therapies in lamivudine-refractory patients with chronic hepatitis B: combined lamivudine and adefovir, and 1-mg entecavir
por: Ze, EunYoung, et al.
Publicado: (2014)

Lamivudine plus adefovir combination therapy for lamivudine resistance in hepatitis-B-related hepatocellular carcinoma patients
por: Kim, Jeong Han, et al.
Publicado: (2013)

Virologic response is not durable after adefovir discontinuation in lamivudine-resistant chronic hepatitis B patients
por: Jung, Young Kul, et al.
Publicado: (2011)

De novo entecavir+adefovir dipivoxil+lamivudine triple-resistance mutations resulting from sequential therapy with adefovir dipivoxil, and lamivudine
por: Yang, Song, et al.
Publicado: (2016)

Viral quasispecies of hepatitis B virus in patients with YMDD mutation and lamivudine resistance may not predict the efficacy of lamivudine/adefovir rescue therapy
por: Wang, Changtai, et al.
Publicado: (2019)

Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response
por: Woo, Hyun Young, et al.
Publicado: (2020)

Comparison of the clinical outcomes between antiviral-naïve patients treated with entecavir and lamivudine-resistant patients receiving adefovir add-on lamivudine combination treatment
por: Kim, Hong Joo, et al.
Publicado: (2016)

Efficacy of switching from adefovir to tenofovir in chronic hepatitis B patients who exhibit suboptimal responses to adefovir-based combination rescue therapy due to resistance to nucleoside analogues (SATIS study)
por: Lee, Hye Won, et al.
Publicado: (2016)

Meta-analysis: Adefovir dipivoxil in combination with lamivudine in patients with lamivudine-resistant hepatitis B virus
por: Chen, En-Qiang, et al.
Publicado: (2009)

Successful rescue therapy with tenofovir in a patient with hepatic decompensation and adefovir resistant HBV mutant
por: Ratziu, Vlad, et al.
Publicado: (2006)

Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy
por: Park, Jung Gil, et al.
Publicado: (2015)

Efficacy and safety of entecavir versus lamivudine over 5 years of treatment: A randomized controlled trial in Korean patients with hepatitis B e antigen-negative chronic hepatitis B
por: Lee, Kwan Sik, et al.
Publicado: (2017)

Combination therapy of lamivudine and adefovir in Japanese patients with chronic hepatitis B
por: Shakado, Satoshi, et al.
Publicado: (2008)

Hepatitis B surface antigen levels at 6 months after treatment can predict the efficacy of lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B
por: Kim, Jeong Han, et al.
Publicado: (2014)

Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis
por: Sheng, Yun-Jian, et al.
Publicado: (2011)

Effects of Entecavir and Tenofovir on Renal Function in Patients with Hepatitis B Virus-Related Compensated and Decompensated Cirrhosis
por: Park, Jihye, et al.
Publicado: (2017)

Lamivudine plus adefovir is a good option for chronic hepatitis B patients with viral relapse after cessation of lamivudine treatment
por: Wang, Zhao, et al.
Publicado: (2011)

Lamivudine/Adefovir Treatment Increases the Rate of Spontaneous Mutation of Hepatitis B Virus in Patients
por: Pereira-Gómez, Marianoel, et al.
Publicado: (2016)

Tenofovir vs lamivudine plus adefovir in chronic hepatitis B: TENOSIMP-B study
por: Rodríguez, Manuel, et al.
Publicado: (2017)

Predictors of Refractory Ascites Development in Patients with Hepatitis B Virus-Related Cirrhosis Hospitalized to Control Ascitic Decompensation
por: Seo, Ju Hee, et al.
Publicado: (2013)

Lamivudine versus Entecavir for Newly Diagnosed Hepatitis B Virus-Related Hepatocellular Carcinoma
por: Kim, Jung Hee, et al.
Publicado: (2016)

Long-term Outcome after Prophylactic Lamivudine Treatment on Hepatitis B Virus Reactivation in Non-Hodgkin's Lymphoma
por: Kim, Jin Seok, et al.
Publicado: (2007)

Telbivudine and adefovir combination therapy for patients with chronic lamivudine-resistant hepatitis B virus infections
por: Lin, Ming-Tsung, et al.
Publicado: (2013)

Comparison of the Efficacies and Safety of Combined Therapy between Telbivudine Plus Adefovir and Lamivudine Plus Adefovir in Patients with Hepatitis B Virus Infection in Real-World Practice
por: Lin, Ming-Tsung, et al.
Publicado: (2016)

Safety and efficacy of tenofovir in chronic hepatitis B-related decompensated cirrhosis
por: Lee, Soon Kyu, et al.
Publicado: (2017)

Laboratory Evaluation of Three Regimens of Treatment of Chronic Hepatitis B: Tenofovir, Entecavir and Combination of Lamivudine and Adefovir
por: Jayakumar, Rajeswari, et al.
Publicado: (2012)

Cost-effectiveness analysis of lamivudine, telbivudine, and entecavir in treatment of chronic hepatitis B with adefovir dipivoxil resistance
por: Wang, Guiliang, et al.
Publicado: (2015)

Spontaneous Bacterial Peritonitis in Patients with Hepatitis B Virus-Related Liver Cirrhosis: Community-Acquired versus Nosocomial
por: Kim, Seung Up, et al.
Publicado: (2012)

Chemical pleurodesis for the management of refractory hepatic hydrothorax in patients with decompensated liver cirrhosis
por: Lee, Woo Jin, et al.
Publicado: (2011)

Lamivudine-resistant rtL180M and rtM204I/V are persistently dominant during combination rescue therapy with entecavir and adefovir for hepatitis B
por: WANG, YANG, et al.
Publicado: (2016)

Entecavir monotherapy versus de novo combination of lamivudine and adefovir for compensated hepatitis B virus-related cirrhosis: a real-world prospective multicenter cohort study
por: Wu, Xiaoning, et al.
Publicado: (2019)

The Author's Response: Anti-Viral Therapy for Compensated Liver Cirrhosis Patients with Normal Alanine Aminotransferase
por: Lee, Junggyu, et al.
Publicado: (2016)

High effectiveness of peginterferon alfa-2a plus ribavirin therapy in Korean patients with chronic hepatitis C in clinical practice
por: Heo, Nae-Yun, et al.
Publicado: (2013)

Evaluation of adefovir & lamivudine in chronic hepatitis B: Correlation with HBV viral kinetic, hepatic-necro inflammation & fibrosis
por: Pradeep, Kumar S, et al.
Publicado: (2011)

Combination lamivudine and adefovir versus entecavir for the treatment of naïve chronic hepatitis B patients: A pilot study
por: Du, Qing-Wei, et al.
Publicado: (2013)

Switching Lamivudine with Adefovir Dipivoxil Combination Therapy to Entecavir Monotherapy Provides Better Viral Suppression and Kidney Safety
por: Lian, Jiang-Shan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_2go56plil1r5fpapc6cq2hm4f2